Vitiligo Therapeutics - Pipeline Assessment and Market Forecasts to 2019

Jan. 3, 2012 - PRLog -- GlobalData estimated the global vitiligo therapeutics market to be worth $1.4 billion in 2011. It is expected to grow to $2.7 billion by 2019 at a Compound Annual Growth Rate (CAGR) of 8.8%. This growth can be primarily attributed to the rise in the number of patients undergoing treatment for vitiligo and the launch of Scenesse (afamelanotide) in 2014. The vitiligo therapeutics market will witness only one new drug approval in the forecast period. The new introduction in the market will be positioned as a novel therapy among moderately efficacious generics and is expected to be launched at a premium price, thus limiting its market penetration in initial years. The market will be characterized with the dominance of generic products as only one new product is scheduled to be launched in the forecast period.

The prominence of generics in the market and the new drug introduction will lead to steady growth in the vitiligo therapeutics market over the forecast period. The market is expected to witness moderate growth with generics playing a major role in the forecast period, which is similar to the present market scenario.

GlobalData assessed the current competitive landscape for vitiligo drugs and found that competition is weak. All the available treatment options are moderately successful in meeting the market demand. Although the market has various treatment options available, none are able to manage vitiligo adequately. The products currently available in the market are associated with average efficacy and safety profiles. While current treatment options are capable of inducing some degree of repigmentation in the affected areas, they lack in ceasing disease progression and to impart satisfactory levels of repigmentation.

As the products currently in the market do not serve the unmet need, the market continues to offer opportunities for products in the pipeline with novel mechanism of action and disease modifying characteristics. The unmet need in the vitiligo therapeutics market is considered to be significant and can be fulfilled by technologically advanced products with improved safety and efficacy profiles.

For Sample Pages, please click or add the below link to your browser:
http://www.globaldata.com/reportstore/RequestSamplePages....

GlobalData’s research indicates that the vitiligo therapeutics market pipeline is weak as the pipeline has few therapeutic treatment options. There are seven potential treatment options in the pipeline across various phases of clinical development. Out of the seven pipeline candidates, three are melanocytes transplantation therapies and the remaining four are therapeutic treatments. None of the therapeutic treatment options in the pipeline is in the late stage of development. In Phase III there are three melanocytes transplantation therapies, which will improve the disease management through surgical treatment options. In terms of therapeutic treatment options there are only two first-in-class molecules, one each in Phase II and the preclinical phase of development. The only first-in-class molecule in Phase
II, Scenesse (afamelanotide) from Clinuvel Pharmaceuticals, acts by stimulating alpha-melanocytes and the first-in-class molecule from the preclinical phase, DRM02 of Dermira, is a topical kinase inhibitor. Scenesse is an analogue of alpha melanocytes stimulating hormone and mimics its action. Treatment of
vitiligo patients with Scenesse is expected to facilitate repigmentation by enhancing the growth of melanocytes, assisting in their migration to depigmented areas of skin and activating pigment production within these regions.
GlobalData, the industry analysis specialist, has released its new report, “Vitiligo Therapeutics - Pipeline Assessment and Market Forecasts to 2019”. The report is an essential source of information and analysis on the global Vitiligo Therapeutics market. The report identifies the key trends shaping and driving the global Vitiligo Therapeutics market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global Vitiligo Therapeutics sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.

For further details, please click or add the below link to your browser:
http://www.globaldata.com/reportstore/Report.aspx?ID=Viti...

Visit our report store: http://www.globaldata.com/reportstore

For more details contact:
pressreleases@globaldata.com
           
North America:    +1 646 395 5477
Europe:        +44 207 753 4299
           +44 1204 543 533
Asia Pacific:       +91 40 6616 6782

# # #

GlobalData is a global market intelligence services company providing information research and analysis products and services.